These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28135039)

  • 1. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
    Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
    Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
    Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
    Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
    Lin Q; Zhang H; Ding H; Qian J; Lizaso A; Lin J; Han-Zhang H; Xiang J; Li Y; Zhu H
    J Transl Med; 2019 Aug; 17(1):298. PubMed ID: 31470866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
    Marchetti A; Felicioni L; Malatesta S; Grazia Sciarrotta M; Guetti L; Chella A; Viola P; Pullara C; Mucilli F; Buttitta F
    J Clin Oncol; 2011 Sep; 29(26):3574-9. PubMed ID: 21825258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
    Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
    Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
    Wu H; Feng J; Lu S; Huang J
    Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with non-small-cell lung cancer harbouring a
    Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
    Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
    Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma.
    Zheng D; Wang R; Pan Y; Zheng S; Zhang Y; Li H; Cheng C; Gong R; Li Y; Shen X; Hu H; Cai D; Cheng X; Sun Y; Chen H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1284-91. PubMed ID: 26202550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
    Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
    PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
    Ambrosini-Spaltro A; Rengucci C; Capelli L; Chiadini E; Calistri D; Bennati C; Cravero P; Limarzi F; Nosseir S; Panzacchi R; Valli M; Ulivi P; Rossi G
    Curr Oncol; 2023 Nov; 30(11):10019-10032. PubMed ID: 37999148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.
    Litvak AM; Paik PK; Woo KM; Sima CS; Hellmann MD; Arcila ME; Ladanyi M; Rudin CM; Kris MG; Riely GJ
    J Thorac Oncol; 2014 Nov; 9(11):1669-74. PubMed ID: 25436800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.